Skin Cancer

SKIN CANCER ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

T-VEC Shows Promise as Neoadjuvant Therapy in Melanoma

Investigators compared recurrence-free survival and overall survival outcomes in patients randomly assigned to receive neoadjuvant talimogene laherparepvec (T-VEC) followed by immediate surgery or surgery alone.
A Statistical Fallacy Might Mar Study Findings on Bevacizumab in Melanoma

“‘Trended strongly’ is code for ‘we failed to meet statistical significance,’” remarked one expert, when she was asked to scrutinize the conclusions of a recent post hoc analysis.
Effects of Drugs Targeting Mitochondrial Respiration in Melanoma

Despite relying on glycolysis, there is growing evidence that many tumor types still have high levels of mitochondrial energy metabolism and functioning oxidative phosphorylation. One such subset of tumors is melanoma, potentially playing a role in both tumor progression and resistance to therapy. This has led researchers to wonder whether targeting mitochondrial respiration could be…
Research Shows Long-Term Benefit for Adjuvant Targeted Therapies in High-Risk Melanoma

More than half of patients with resected stage 3 melanoma with BRAF V600E or V600K mutations receiving a year’s worth of adjuvant dabrafenib and trametinib were still alive 5 years later.
How Do Melanoma Comorbidities Affect Patient Treatment Preferences?

Comorbidities can have an impact on what you as a medical professional think is the best course of treatment for your patients. Can they also affect a patient’s thinking on treatment? Comorbidities such as cardiovascular disease, hypertension, and depression can contribute to how a patient’s body responds to treatment and its attendant stress. A recent…

VIDEO SERIES

Recent Advances in Melanoma Therapy

Targeted Treatments and Immunotherapies for Melanoma

Tailoring Treatments in Melanoma

Drug Resistance in Melanoma

Affordability of Melanoma Care

Melanoma: Treatment-induced Toxicity

Immunotherapy: A Decade of Improvements in Melanoma

Should Patients With Melanoma Receive Targeted Therapy or Immunotherapy First?

Melanoma: Checkpoints in the Pipeline

Targeting Therapy for Melanoma Subtypes

Melanoma: Targetable Genes in the Pipeline

Clinical Trials in Melanoma

SKIN CANCER NEWS

African American black woman female patient with White doctor

Black Patients With Merkel Cell Carcinoma Experience Treatment Delays

January 13, 2021

Basal cell carcinoma

Reflectance Confocal Microscopy vs Biopsy for Diagnosis of Basal Cell Carcinoma

January 6, 2021

G-CSF Pretreatment Ameliorates the Activity of an Autologous DC-Based Vaccine in Melanoma

November 13, 2020

Neoadjuvant CMP-001 Plus Nivolumab Found Active in Stage III Melanoma

November 12, 2020

A phase 3 trial looking at nivolumab and ipilimumab in advanced melanoma has reported increased survival with the combination, but notable toxicities.

BEMPEG Plus Nivolumab Induces Durable Responses in Metastatic Melanoma

November 12, 2020

Next post in Skin Cancer

Investigators compared recurrence-free survival and overall survival outcomes in patients randomly assigned to receive neoadjuvant talimogene laherparepvec (T-VEC) followed by immediate surgery or surgery alone.

T-VEC Shows Promise as Neoadjuvant Therapy in Melanoma